Sirion Therapeutics Inc.
This article was originally published in Start Up
Executive Summary
Fenretinide, Sirion Therapeutics' lead candidate, targets the pathway by which Vitamin A gets into the eye and becomes part of A2E, the protein complex that scientists consider a bad actor in AMD. Intermediate analysis of fenretinide Phase II data showed that patients taking the compound had slower growth of lesions than those given placebo, and that trend increased over time.
You may also be interested in...
Acucela Strikes Third Ophthalmology Deal With Otsuka For Glaucoma Drug
Seattle-based ophthalmology specialist Acucela has struck its third partnership with Japanese pharma Otsuka Pharmaceutical Co., this time to collaborate on development of a preclinical glaucoma treatment
Acucela Strikes Third Ophthalmology Deal With Otsuka For Glaucoma Drug
Seattle-based ophthalmology specialist Acucela has struck its third partnership with Japanese pharma Otsuka Pharmaceutical Co., this time to collaborate on development of a preclinical glaucoma treatment
Acucela Strikes Third Ophthalmology Deal With Otsuka For Glaucoma Drug
Building on deals in AMD and dry eye, the U.S. eye care startup will conduct trials on a novel glaucoma treatment, with an option to co-promote.